467 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

068IC - Surgical & Medical Management of High-Risk Renal Cell Carcinoma: New Paradigms for Treatment

Sunday, May 15, 2022

4:00 PM – 6:00 PM

Location: Room 208

Instructional Course Director(s)

Benjamin R. Lee, MD

Professor & Chair, The George W. Drach, MD Endowed Chair, Department of Urology
University of Arizona College of Medicine

Instructional Course Faculty(s)

AS

A. Oliver Sartor, MD

Tulane Medical School
CS

Chandru P. Sundaram, MD, FACS, FRCS

Welch Professor of Urology, Vice Chair and Program Director
Indiana University

Learning Objectives:

Discuss new FDA approved checkpoint inhibitors for treatment and counseling of advanced renal cell carcinoma.
Identify indications, risks and benefit of neoadjuvant tyrosine kinase inhibitors for downsizing renal cell carcinoma.
Identify appropriate treatment options for management of complex cases.

Treatment of renal cell carcinoma (RCC) has changed with expanding indications for robotic partial nephrectomy and inclusion of new Food and Drug Administration (FDA) approved treatments for advanced RCC. This course will focus on didactic case discussions using videotape analysis of surgical treatment, setup and successful completion of robotic partial nephrectomy, complication management and how to optimize outcomes. Urologists are now faced with treatment of advanced RCC with a host of options, from tyrosine kinase inhibitors to checkpoint inhibitors, with an update on active clinical trials. There will be discussion focus on how to monitor, and algorithms for when to switch treatment.